Deferred Share Option Awards

RNS Number : 5871J

Eco Animal Health Group PLC

13 December 2022

 

13 December 2022

ECO Animal Health Group plc

("ECO" or the "Company")

Deferred Share Option Awards to Executive Director & PDMRs

ECO Animal Health Group plc announces that on 12 December 2022, deferred nominal cost share options were granted under the Company's Deferred Bonus Plan ("DBS") over 45,606 ordinary shares in the Company (representing approximately 0.07 percent of the Company's issued share capital) to an Executive Director and members of the Company's Executive Leadership Team ("ELT") listed below. These awards relate to the deferral of 33% and 20% of the annual bonus for Executive Directors and members of ELT respectively earned in respect of the Company's financial year ended 31 March 2022.

Name	Position	Number of Deferred Share Options
Chris Wilks	Chief Financial Officer	4,309
Hafid Benchaoui	Head of Global Research and Development	3,666
Andrew Buglass	Business Unit Head - China & Japan	6,872
Seamus Long	Global Director of Operations	2,260
Jordi Mora	Global Technical Services Director	4,507
Piotr Postepski	Global Director of Sales	14,926
Oscar Romero-Galindo	Head of Global Marketing	9,066

As indicated in the Circular to shareholders dated 4 February 2021, the DBS has been established to allow the Remuneration Committee to require a significant part of the annual bonuses paid to Executive Directors and senior management to be deferred in exchange for an award of nominal cost options which vest after 3 years.

For further information please contact:

ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO) 020 8447 8899 IFC Advisory Graham Herring Zach Cohen 020 3934 6630 Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies George Tzimas 020 7496 3000 Investec (Joint Broker) Gary Clarence Daniel Adams Carlo Spingardi 020 7597 5970 Equity Developments Hannah Crowe Matt Evans 020 7065 2692 About ECO Animal Health ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

PDMR Notification - ECO DBS Deferred Share Option Awards

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	1.  Chris Wilks 2.  Hafid Benchaoui 3.  Andrew Buglass 4.  Seamus Long 5.  Jordi Mora 6.  Piotr Postepski 7.  Oscar Romero-Galindo
2.	Reason for the notification
a.	Position/status	1.  Chief Financial Officer 2. Head of Global Research and Development 3.  Business Unit Head - China & Japan 4.  Global Director of Operations 5.  Global Technical Services Director 6.  Global Director of Sales 7.  Head of Global Marketing
b.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Eco Animal Health Group Plc
b.	LEI	2138009XN9DJ3YP70B55
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Options over ordinary shares of 5p each. GB0032036807
b.	Nature of the transaction	Award of nominal cost share options under the Company's DBS.
c.	Price(s) and volume(s)	Numbers 1 to 7 in the left-hand column correspond to the relevant PDMR as detailed in boxes 1a and 2a above. Price(s) Volume(s) 1. 5p 4,309 2. 5p 3,666 3. 5p 6,872 4. 5p 2,260 5. 5p 4,507 6. 5p 14,926 7. 5p 9,066
d.	Aggregated information Aggregated volume Price	n/a
e.	Date of the transaction	12 December 2022
f.	Place of the transaction	Outside a trading venue.

 

END

 

 

DSHGPGMCPUPPGAW